|
|
|
| home > ebr > current issue |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
Editor’s Letter
EBR's Editor, Dr Deborah O'Neil, details all the innovations touched upon in this issue and how the majority can enhance cancer treatment.
|
|
|
|
|
Label-Free Biosensing
Protein Progression
Following a significant increase in quality, peptide and protein microarrays now have the potential to offer brand new opportunities in pharmaceutical and proteomics R&D, claims Güenther Proll at Biametrics.
|
|
|
|
Process-Specific Versus Generic Host Cell Protein Impurity Assays
Biologics Process Analysis
Given the rise in therapeutic antibody production, it has become more important than ever to address issues associated with host cell proteins, as detailed by Ken Hoffman, Eric Bishop, Dr Alla Zilberman, and Dr Jared Isaac at Cygnus Technologies.
|
|
|
|
Generating High-Quality Protein Reagents from Eukaryotic Cells
Cell Culture Considerations
Both Escherichia coli and eukaryotic systems have their pros and cons, yet the former is selected more often due to speed and cost implications. Dr Mark Abbott at Peak Proteins discusses the factors to be considered.
|
|
|
|
Improving Pharmacokinetic Assays in a Regulatory Bioanalysis Setting
Applying Affimers
Dr Amanda Nicholl at Avacta Life Sciences expresses the fundamentality of pharmacokinetic assay results in the phases of drug development and how to increase the effectiveness and efficacy of antibody drug development.
|
|
|
|
Peptides in Plasma
Determining Peptides
Determination in plasma can be particularly complicated, especially when dealing with peptides, but Professor Hermann Mascher at pharm-analyt believes it is still a route worth taking.
|
|
|
|
|
|
Purifying Oligonucleotides
Produce Potential
Dr Cecilia Unoson and Dr Lars Haneskog at Bio-Works Technologies delve into whether the necessary yield and purity of oligonucleotides can be attained through anion exchange chromatography.
|
|
|
|
|
|
Advanced Therapies
Rising to the Challenge
Dr Fiona Thistlethwaite at The Christie Hospital and Dr Ian Thomas at Aptus Clinical explore the challenges of bringing advanced therapy medicinal products to market and the considerations that must be made.
|
|
|
|
Tissue-Agnostic Approvals
A New Oncology Era
New advances in tumourigenesis have laid the foundations for a molecular marker that assists in defining and treating cancers, explains Dr Terese Johansson at NDA Group.
|
|
|
|
Cancer Therapy Innovations
Oncological Advances
Dr Kathryn D Bungartz at N-of-One provides an overview of how advanced imaging techniques and improved preventative measures have transformed the world of cancer innovation.
|
|
|
|
In Vitro Bioassays
Candidate Selection
The cancer immunotherapies field has made notable progress in its clinical application, and combination therapies may be a viable force to drive these advancements further, suggest Thibault Janss and Sofie Pattijn at ImmunXperts.
|
|
|
|
Diafiltration of Antibody-Drug Conjugates
Novel TFF Capsule Evaluation
The teams at Sanofi and Merck Group demonstrate the advantages of antibody-drug conjugates as cancer chemotherapeutics.
|
|
|
|
|
|
Electroceutical Therapy for Chronic Pain
Effective Electroceuticals
Dr Sree Koneru at BioElectronic Corporation and Dr Kenneth McLeod at the State University of New York in Binghamton, outline the benefits of electroceutical treatments for many neurological disorders and compare this to the widely recognised central sensitisation.
|
|
|
|
Benefits of Bioelectronic Medicine
Theory to Game Changer
As the use of bioelectronics is on the rise following the adoption of electric devices as main treatment options, Pascaline Vancraeyenest at Healtech identifies how the reliance on drugs is potentially becoming limited.
|
|
|
|
The Future of Bioelectronic Medicine
Targeted Technology
Dr Deepak B Thimiri Govinda Raj, Prasanna Subramaniam, Dr Sri Saran Venkatachalam, and Dr Dinh-Toi Chu at Envirotransgene Biosolutions examine why bioelectronic medicine is regarded as a disruptive technology in healthcare.
|
|
|
|
|
|
In Brief
GOAL!
Following this year's approval of the first RNA interference-based human therapy, EBR's Industry Advisor, Emile Bellott, takes a look at its new role as a game-changer within the biopharma industry.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Digital Manufacturing is a top priority for Life Sciences according to Zenith survey
Zenith Technologies, a world leader in delivering GMP manufacturing
software solutions to the life sciences industry, recently conducted an
industry survey that suggests the digital manufacturing is a top
priority.
More info >> |
|
 |
White Papers |
 |
|
Speciality Logistics Outlook 2015
World Courier
To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >> |
|
 |
Industry Events |
 |
ASGCT 22nd Annual Meeting
29 April - 2 May 2019, Washington Hilton, Washington, D.C
The 2019 ASGCT Annual Meeting is expected to be the largest in Society
history, eclipsing the mark set by the 2018 meeting just last year. Join more
than 3,500 researchers, clinicians, advocates, and industry leaders in
discovering the latest science and technology surrounding gene and cell
therapy.
More info >> |
|
|
